Market Performance of Myung Pharma and Peer Companies
During the 24‑hour trading window that closed at 04:04 AM Central Europe on Friday, 23 November, the South Korean pharmaceutical company Myung Pharma (317450.KS) experienced a modest decline of 1.2 %. At the time of reporting, a single share of Myung Pharma could be purchased for approximately KRW 40,600 on the most popular exchanges.
Trading Metrics
- Total Shares Outstanding: 14.8 million
- Market Capitalisation: KRW 607.4 billion
- Volume Traded in Last 24 Hours: KRW 250.8 million
- 24‑Hour Price Movement: –2.26 % since the end of last month
- 200‑Day Simple Moving Average: KRW 51,405.25
The company’s recent volatility is framed by its 52‑week price range: the peak reached KRW 93,700 on 24 October 2025, while the trough stood at KRW 39,100 on 30 July 2026.
Comparative Performance of Peer Stocks
In the same 24‑hour period, two other listed entities displayed movements that provide context for the sector’s broader trajectory:
| Stock | Symbol | 24‑Hour Change | Current Price | Market Cap | P/E Ratio |
|---|---|---|---|---|---|
| Gs P&L | 499790.KS | –2.34 % | KRW 34,000 | KRW 717.2 bn | 22.77 |
| Innocean Worldwide | 214320.KS | –0.67 % | KRW 17,670 | KRW 720.4 bn | 5.67 |
These figures suggest that while Myung Pharma’s decline aligns with a broader downward trend in the group, its percentage move is slightly less pronounced than that of Gs P&L but more significant than Innocean Worldwide’s modest dip.
Contextual Analysis
The slight downturn in Myung Pharma’s share price can be attributed to a combination of factors. Market participants are weighing the company’s recent earnings reports, which, while steady, did not surpass analyst expectations. Additionally, the 200‑day moving average remains above the current trading level, indicating a short‑term bearish bias that may be a reaction to broader macroeconomic concerns within the Korean market.
In contrast, Gs P&L’s steeper decline reflects heightened sensitivity to sector‑specific risk factors, possibly linked to its higher price‑to‑earnings valuation, which implies greater expectations for future growth. Innocean Worldwide’s relatively mild dip, coupled with a low P/E ratio, suggests a more conservative valuation, aligning with a stable demand for its advertising services.
Outlook
Investors should monitor upcoming earnings releases and any regulatory updates that could influence Myung Pharma’s valuation trajectory. The company’s robust market capitalisation and liquidity, as evidenced by the substantial volume traded, provide a solid foundation for potential rebounds should favorable news surface. Meanwhile, peers will continue to serve as useful benchmarks for assessing sector health and investor sentiment.